Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$76.15 USD

76.15
421,444

+0.21 (0.28%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $76.11 -0.04 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Charles River's (CRL) Improved Volume Aids Amid Margin Woe

by Zacks Equity Research

Charles River (CRL) registers growth in small research models, research model services and the Cell Solutions business.

Charles River (CRL) Introduces LVV Packaging Plasmids

by Zacks Equity Research

Charles River (CRL) launches packaging plasmids to accelerate and standardize lentiviral vector development.

Globus Medical (GMED) to Gain From NUVA Merger Amid Margin Woe

by Zacks Equity Research

Globus Medical (GMED) continues to make significant progress in launching its prone lateral patient positioning system.

Charles River (CRL) Inks a CDMO Partnership for Bladder Cancer

by Zacks Equity Research

Curigin's oncolytic RNAi gene therapies are set to leverage Charles River's (CRL) expertise in CDMO solutions.

Myriad Genetics' (MYGN) New Pact to Use MRD Testing Platform

by Zacks Equity Research

Myriad Genetics (MYGN) announces research collaboration with MD Anderson on metastatic RCC with its high-definition MRD research testing platform based on whole-genome sequencing.

Inspire (INSP) Gets FDA Nod for Expanded Indication of AHI

by Zacks Equity Research

The FDA approves Inspire's (INSP) application to expand the indication to include patients with AHI up to 100 events per hour.

VREX vs. HAE: Which Stock Is the Better Value Option?

by Zacks Equity Research

VREX vs. HAE: Which Stock Is the Better Value Option?

Earnings Estimates Moving Higher for Haemonetics (HAE): Time to Buy?

by Zacks Equity Research

Haemonetics (HAE) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Walgreens Boots (WBA) Gains From New Alliances Amid Macro Woes

by Zacks Equity Research

Continued slowdown in generic introduction has been affecting Walgreens Boots' (WBA) margins.

Neogen (NEOG) Introduces 2 Assays for Histamine Detection

by Zacks Equity Research

Neogen (NEOG) launches Reveal for Histamine and Reveal Q+ for Histamine assays for the detection of Histamine.

Haemonetics (HAE) Hospital Arm Grows, Plasma Volume Improves

by Zacks Equity Research

Within Haemonetics (HAE) Vascular Closure, growth is led by the opening of new accounts and increasing penetration to gain share in the top U.S. EP hospitals.

Are Medical Stocks Lagging Alimera Sciences (ALIM) This Year?

by Zacks Equity Research

Here is how Alimera Sciences (ALIM) and Haemonetics (HAE) have performed compared to their sector so far this year.

Here's Why You Should Invest in Haemonetics (HAE) Right Now

by Zacks Equity Research

Investors are optimistic about Haemonetics (HAE), led by the impressive performance of Plasma and Hospital businesses.

Here's Why Haemonetics (HAE) is a Strong Growth Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

How Much Upside is Left in Haemonetics (HAE)? Wall Street Analysts Think 27.09%

by Zacks Equity Research

The mean of analysts' price targets for Haemonetics (HAE) points to a 27.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

New Strong Buy Stocks for May 26th

by Zacks Equity Research

HDELY, WIRE, HAE, GWW and MUSA have been added to the Zacks Rank #1 (Strong Buy) List on May 26, 2023.

HAE or PODD: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HAE vs. PODD: Which Stock Is the Better Value Option?

Is Apyx Medical (APYX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Apyx Medical (APYX) and Haemonetics (HAE) have performed compared to their sector so far this year.

Haemonetics (HAE) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Amid a challenging economic environment, Haemonetics (HAE) delivers impressive fiscal fourth-quarter organic revenues, led by the stellar performance across the Plasma and Hospital business.

Here's What Key Metrics Tell Us About Haemonetics (HAE) Q4 Earnings

by Zacks Equity Research

While the top- and bottom-line numbers for Haemonetics (HAE) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Haemonetics (HAE) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Haemonetics (HAE) delivered earnings and revenue surprises of 13.24% and 6.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Verano Holdings Corp. (VRNOF) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Verano Holdings Corp. (VRNOF) delivered earnings and revenue surprises of 57.14% and 0.78%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

VREX or HAE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

VREX vs. HAE: Which Stock Is the Better Value Option?

HAE vs. SYK: Which Stock Is the Better Value Option?

by Zacks Equity Research

HAE vs. SYK: Which Stock Is the Better Value Option?

Is Butterfly Network (BFLY) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Butterfly Network, Inc. (BFLY) and Haemonetics (HAE) have performed compared to their sector so far this year.